Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Palandri

Showing results (41-50 of 187) with videos related to

Pageof 19
Sort By:
Frontiers in Oncology|March 24, 2025
Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitalsFrancesca Palandri, Alessandro Inzoli, Antonella Barone, et al.
European Journal of Haematology|November 1, 2022
Management of polycythemia vera: A survey of treatment patterns in ItalyGiuseppe Alberto Palumbo, Massimo Breccia, Claudia Baratè, et al.
Journal of Cancer Research and Clinical Oncology|November 22, 2021
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia veraCarl C Crodel, Kathleen Jentsch-Ullrich, Marcel Reiser, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|May 24, 2008
Association between "sarcoidosis-like" disease and common variable immunodeficiency (CVI): a new CVI variant showing an activation of the immune systemAlessandra Vultaggio, Andrea Matucci, Paola Parronchi, et al.
American Journal of Hematology|February 12, 2009
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapyFrancesca Palandri, Lucia Catani, Nicoletta Testoni, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|December 2, 2025
The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysisValentina Biagioli, Alessandro Inzoli, Antonella Barone, et al.
Leukemia & Lymphoma|February 27, 2026
Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survivalAndrew T Kuykendall, Francesca Palandri, Mirko Fillbrunn, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Talanta|October 24, 2025
Hollow fiber flow field-flow fractionation enables high-quality Extracellular Vesicle isolation from minimal plasma samples in polycythemia vera liquid biopsyGhazal Narimanfar, Anna Placci, Filippo Maltoni, et al.
Cancers|April 12, 2022
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary MyelofibrosisDaniele Cattaneo, Claudia Vener, Elena Maria Elli, et al.
Pageof 19

Showing results (41-50 of 187) with videos related to

Sort By:
Pageof 19
Frontiers in Oncology|March 24, 2025
Anemia and blood transfusions in myelofibrosis: economic and organizational impact on Italian patients, caregivers and hospitalsFrancesca Palandri, Alessandro Inzoli, Antonella Barone, et al.
European Journal of Haematology|November 1, 2022
Management of polycythemia vera: A survey of treatment patterns in ItalyGiuseppe Alberto Palumbo, Massimo Breccia, Claudia Baratè, et al.
Journal of Cancer Research and Clinical Oncology|November 22, 2021
Cytoreductive treatment in real life: a chart review analysis on 1440 patients with polycythemia veraCarl C Crodel, Kathleen Jentsch-Ullrich, Marcel Reiser, et al.
Sarcoidosis, Vasculitis, and Diffuse Lung Diseases : Official Journal of WASOG|May 24, 2008
Association between "sarcoidosis-like" disease and common variable immunodeficiency (CVI): a new CVI variant showing an activation of the immune systemAlessandra Vultaggio, Andrea Matucci, Paola Parronchi, et al.
American Journal of Hematology|February 12, 2009
Long-term follow-up of 386 consecutive patients with essential thrombocythemia: safety of cytoreductive therapyFrancesca Palandri, Lucia Catani, Nicoletta Testoni, et al.
European Journal of Oncology Nursing : the Official Journal of European Oncology Nursing Society|December 2, 2025
The influence of patient engagement and self-efficacy on self-care in myeloproliferative neoplasms: A mediation analysisValentina Biagioli, Alessandro Inzoli, Antonella Barone, et al.
Leukemia & Lymphoma|February 27, 2026
Ruxolitinib treatment for myelofibrosis with anemia: a retrospective assessment of real-world patient characteristics, treatment patterns, and survivalAndrew T Kuykendall, Francesca Palandri, Mirko Fillbrunn, et al.
Future Oncology (London, England)|June 6, 2025
Indirect treatment comparisons of momelotinib vs pacritinib safety and anemia outcomes in patients with myelofibrosisLucia Masarova, Srdan Verstovsek, Francesca Palandri, et al.
Talanta|October 24, 2025
Hollow fiber flow field-flow fractionation enables high-quality Extracellular Vesicle isolation from minimal plasma samples in polycythemia vera liquid biopsyGhazal Narimanfar, Anna Placci, Filippo Maltoni, et al.
Cancers|April 12, 2022
Diabetes and Second Neoplasia Impact on Prognosis in Pre-Fibrotic Primary MyelofibrosisDaniele Cattaneo, Claudia Vener, Elena Maria Elli, et al.
Pageof 19